The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain's Serious Fraud Office re-examines funding model

Tue, 24th May 2016 17:13

By Kirstin Ridley

LONDON, May 24 (Reuters) - The Serious Fraud Office (SFO),Britain's leading fraud and corruption investigator andprosecutor, said on Tuesday it was re-examining a funding modelthat has been criticised for risking weakening investigationsand delaying cases.

So-called "blockbuster funding", under which the agency canrequest extra cash for costly cases directly from thegovernment, was criticised in a report published on Tuesday bythe Crown Prosecution Service Inspectorate (CPSI), which reviewsthe effectiveness of the SFO's structures and governance.

The CPSI said such a model, which allows the SFO to shore upits staffing levels with external experts for big cases, coulddamage investigations, did not provide value for money andprevented the agency from building future expertise in-house.

It said that when it inspected the agency 21 percent ofstaff were not permanent employees.

"There is therefore an inherent lack of consistency in (SFO)teams, which becomes particularly problematic because of thelengthy nature of SFO investigations," the report said. "Thisdisruption increases the risk of delay in cases and may weakenthe investigative strategy going forward."

The CPSI report, which praised the SFO board for improvingthe reputation of the agency externally over the last fouryears, also suggested other reforms such as a smaller managementboard, appointing a chief executive, clearer reporting anddelegation lines for committees and holistic risk management.

SFO head David Green said in an emailed statement that theagency was "giving new consideration" to a funding model he hassaid in the past is not perfect, but which "does the job".

He said the SFO was also carefully considering recommendations such as appointing a CEO or chief operatingofficer and changing the structure of the management board.

Legal experts have already criticised a funding model theyargue could lead to political interference with cases that canconcern influential blue-chip British companies. The SFO'scurrent caseload includes investigations into Barclays,Rolls-Royce and GSK.

The SFO operates on a core annual budget of around 35million pounds ($51 mln), although extra cash injections to payfor costly cases have pushed that up to around 50 million poundsa year over the last few years.

Its biggest and costliest cases have included theinvestigation into the alleged manipulation of financialbenchmarks such as Libor (London interbank offered rate), whichto date has yielded one conviction and one guilty plea.

Five former Barclays traders are on trial at Southwark CrownCourt and further trials of individuals accused of manipulatingEuribor (euro interbank offered rate) are expected to begin nextyear. ($1 = 0.6838 pounds) (Reporting by Kirstin Ridley; Editing by Susan Fenton)

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.